Pagina 2 - I migliori diagnostici di Diagnostica - TOP-31 medici

Il medico dirige il Centro di Melanoma e Immunoterapia del Cancro presso il Centro Medico Hadassah, concentrandosi sulla ricerca innovativa e sul trattamento dei pazienti. Specializzandosi nello studio della famiglia dei recettori SLAM, il medico è in prima linea nella ricerca sulla risposta immunitaria anti-cancro.<\/p>

Coinvolto nel trattamento dei pazienti con melanoma con nuove immunoterapie, il medico lavora con un team di clinici e ricercatori. Questa collaborazione fornisce accesso immediato ai dati clinici e ai tessuti derivati dai pazienti, migliorando gli sforzi di ricerca traslazionale.<\/p>

Il medico è un dermatologo-venereologo esperto e pioniere della chirurgia micrografica in Israele, con oltre 30 anni di esperienza professionale. Specializzandosi nel metodo MOHS, il medico ha contribuito significativamente al campo della dermatologia attraverso tecniche innovative nella rimozione strato per strato delle oncopatologie cutanee.<\/p>

Laureato presso l'Università Medica di Tel Aviv e ha proseguito l'educazione medica presso il Centro Oncologico di Houston, USA. Il medico è un membro attivo delle comunità dermatologiche europee, israeliane e americane e ha scritto circa 100 opere scientifiche e mediche.<\/p>

Il medico è un oncologo altamente esperto con un focus sul trattamento e la gestione del cancro. Con anni di pratica dedicata, il medico ha contribuito in modo significativo ai progressi in oncologia, implementando terapie all'avanguardia e partecipando a ricerche volte a migliorare i risultati dei pazienti. Il medico è riconosciuto per la sua leadership all'interno della comunità oncologica, avendo ricoperto ruoli chiave che guidano l'innovazione e la cura di qualità nel trattamento del cancro. La loro esperienza clinica è completata da un impegno per la cura centrata sul paziente e lo sviluppo professionale continuo.<\/p>

Professor Jair Bar, MD, PhD, is a thoracic oncologist and Deputy Director of the Cancer Center at Sheba Medical Center. He leads the Thoracic Oncology Unit. He treats lung cancer, including advanced non-small cell cases. His care includes medical oncology, radiotherapy, immunotherapy, and targeted therapy.

He runs a translational research lab focused on resistance to immunotherapy. He has published on exhaled-breath cancer metabolism and on angiogenesis inhibition in lung cancer.

He has chaired the Israel Lung Cancer Group since 2003. He is a member of the Israel Society of Clinical Oncology and Radiotherapy, the American Society of Clinical Oncology, and the American Association for Cancer Research. He is board-certified in Medical Oncology and Radiotherapy Oncology. He is a Senior Lecturer at Tel Aviv University.

Dr. David (Dudi) Mishali, MD, is Director of Pediatric and Congenital Cardiothoracic Surgery at Sheba Medical Center. He treats infants and children with congenital heart defects. His work includes rare, high-risk anomalies and complex newborn reconstructions.

He trained internationally. He completed his residency at Rabin Medical Center and clinical fellowships in cardiac surgery at the Cleveland Clinic and in congenital pediatric cardiothoracic surgery at UCSF. He is board certified in cardiothoracic surgery. He developed and implemented minimally invasive methods that reduce surgical trauma and improve cosmetic results.

He is a Senior Lecturer at Tel Aviv University’s Sackler Faculty of Medicine. He has written many peer-reviewed papers and book chapters, including on point-of-care testing in children during cardiopulmonary bypass and on accessory mitral valve tissue. He holds a leadership role at a hospital ranked among the world’s top 10.

Prof. Elad Jacoby, MD, heads the Pediatric Cell Therapy Center at Sheba Medical Center. He is the Medical Director of the Advanced Biotherapy Center. He is a pioneer of pediatric CAR T‑cell therapy in Israel. He led one of the first national leukemia programs. He has almost 20 years of clinical and research experience.

He specializes in CAR T‑cell therapy, bone marrow and stem cell transplantation, and high‑risk pediatric leukemias and lymphomas. He leads international clinical trials and has authored over 240 publications. His collaborations include Johns Hopkins Hospital and the U.S. National Cancer Institute. He is an Associate Professor at Tel Aviv University. He received his MD from Tel Aviv University, completed residency at Sheba Medical Center, and fellowships at Johns Hopkins and the National Cancer Institute. He is board‑certified in Pediatrics and in Pediatric Hematology and Oncology. He serves on the IBFM CAR T‑Cell Taskforce and the Sheba Institutional Review Board. He leads the integration of CAR T‑cell therapy with transplantation.

Professor Pnina Langevich is a rheumatologist and immunologist with over 40 years of experience. She leads the National Center for Rheumatology and Autoimmune Diseases at Sheba Medical Center. Forbes Israel has repeatedly named her among the country’s top doctors.

She is an expert in rheumatoid arthritis, osteoarthritis, joint diseases, systemic lupus erythematosus, scleroderma, and complex autoimmune disorders. She treats severe, treatment‑resistant cases using advanced diagnostics and personalized therapy.

She trained in rheumatology and internal medicine at Sheba. She combines patient care with research on new therapies. She served for 12 years as Vice President of the World Association of Rheumatologists. She is Editor‑in‑Chief of Lupus and a member of the Israeli Medical Association and the International Association of Rheumatologists.

Dr. Zohar Dotan is Head of the Urology Department at Sheba Medical Center. He is a leading uro-oncologist and a pioneer of robotic and laparoscopic urologic surgery in Israel.

He has authored more than 50 scientific publications. He is a regular speaker at international conferences. He has received awards from the American Association of Clinical Surgery, including recognition for research in prostate cancer treatment.

Leadership and credentials: Head of the Israeli Uro-Oncology Society. Assistant Professor at Tel Aviv University. Member of the Israeli, American, and European Urological Associations. Training: MD from Tel Aviv University and a PhD in Genetics. Urology residency at Sheba Medical Center. Fellowship in uro-oncology and laparoscopic surgery at Memorial Sloan Kettering, New York.

Prof. Ben Boursi is a physician in the Gastrointestinal Cancer Department at Sheba Medical Center. He specializes in internal medicine, medical oncology, and cancer epidemiology. He is board certified in internal medicine and medical oncology. He earned a B.Med.Sc (summa cum laude) and an MD (magna cum laude) from Tel Aviv University.

He completed clinical and research fellowships in GI oncology and cancer epidemiology at the University of Pennsylvania. He also completed electives at MD Anderson and Mayo Clinic. He founded the ECOG-ACRIN Microbiome Working Group. His microbiome-oncology research has been published in leading journals, including Science, and highlighted by ASCO.

He developed predictive models for early diagnosis of colorectal and pancreatic cancers. These models are now in clinical evaluation. He holds an academic appointment at Tel Aviv University. He is also an Associate Scholar at the University of Pennsylvania.

Professor Raanan Berger, MD PhD, is a medical oncologist and radiotherapist. He is Director of the Cancer Center at Sheba Medical Center and heads its clinical research unit. He was listed in Forbes Israel’s “Best Doctors” (2025). He leads the genitourinary oncology program with a focus on prostate cancer. His care includes systemic therapy and radiotherapy in a multidisciplinary, patient-centered model.

He is board-certified in oncology. He earned his MD and PhD at Tel Aviv University and completed his clinical training at Sheba. He then completed a postdoctoral fellowship at Dana-Farber/Harvard, focusing on prostate cancer with Dr. Philip Kantoff and molecular oncology in Dr. William C. Hahn’s lab. He is a member of ESMO and ASCO. He has co-authored more than 20 peer-reviewed papers, including studies on outcomes in high- versus very high-risk prostate cancer and on BRCA1/2 in large cohorts.